Key result
Testosterone replacement therapy linked to acute arterial thrombosis in a Klinefelter patient with MTHFR mutation.
Why the study?
Arterial thrombotic events had not been previously reported in Klinefelter syndrome patients, despite known venous thrombosis risk and thrombophilic states.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case report provides the first evidence of arterial thrombotic events in Klinefelter syndrome, highlighting a potential risk when combined with MTHFR mutations and testosterone replacement therapy.
Klinefelter syndrome (KS) is the most common sex chromosome disorder in men. It may be associated with an increased risk for venous thrombosis and thromboembolism, which is partially explained by hypofibrinolysis due to androgen deficiency. Additional genetic or acquired thrombophilic states have been shown in KS patients complicated with venous thrombosis as isolated case reports. Arterial thrombotic events had not been previously reported in KS. In this study, a young man with KS who developed acute arterial thrombosis during testosterone replacement therapy is presented. He was homozygous for the A1298C mutation of the methylenetetrahydrofolate reductase (MTHFR) gene.
No takes yet. Share an insight, caveat, or question.
Özbek et al. (2007) conducted a case report in Klinefelter syndrome and acute arterial thrombosis (n=1). Testosterone replacement therapy and homozygous A1298C mutation of the MTHFR gene was evaluated on Acute arterial thrombosis. A young man with Klinefelter syndrome developed acute arterial thrombosis during testosterone replacement therapy, associated with a homozygous A1298C mutation of the MTHFR gene.
Synapse has enriched 10 related papers. Consider them for comparative context: